Law Firms Press Soleno Investors to Seek Lead Role in Securities Suit by May 5

Overview

• Hagens Berman, which issued a notice Thursday, urged Soleno investors to petition for lead‑plaintiff status by May 5, 2026.
• The case, City of Pontiac Police & Fire Retirement System v. Soleno Therapeutics, Inc. (No. 3:26‑cv‑01979), is filed in the Northern District of California for investors who bought shares from March 26 to November 4, 2025.
• The complaint alleges Soleno downplayed safety signals for VYKAT XR (DCCR), including excess fluid retention and possible heart failure in children, and overstated early launch demand through inflated “start form” counts.
• Coverage cites two market shocks tied to these issues, including a Scorpion Capital report on August 15, 2025, and company disclosures on November 4, 2025 that preceded a roughly 26% one‑day drop in SLNO shares.
• At the time of the filing, DCCR was Soleno’s only commercial product for treating hyperphagia in people with Prader‑Willi syndrome, a fact that could magnify any safety concerns for families, doctors, and investors.